Department of Surgery, Division of Acute Care Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA, United States of America.
Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, VA, United States of America.
PLoS One. 2019 May 1;14(5):e0215386. doi: 10.1371/journal.pone.0215386. eCollection 2019.
Novel crystalloid solutions containing polyethylene glycol polymers (PEG-20k) produce dramatic resuscitation effects but dose-dependently produce a hypocoagulative state. The objective of this study was to examine possible mechanisms of this effect. Based on previous thromboelastography data, we hypothesize the effect is largely due to platelet interactions with the polymers.
Whole citrated blood from healthy volunteers was diluted ex-vivo 10% with crystalloids and tested for coagulation and platelet function. The specific tests included prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and von Willebrand factor (vWf) activity, thrombin generation, thromboelastography with and without platelet mapping, platelet flow cytometry, and erythrocyte sedimentation rate.
Fibrinogen and vWF activities, PT, and aPTT were not affected by PEG-20k dilutions. Thrombin activity was mildly suppressed with PEG-20k (TTP- 20%). Platelet mapping demonstrated significantly greater % inhibition of both ADP and arachidonic acid-induced platelet aggregation with PEG-20k, but direct ADP-activated gpIIa/IIIb (PAC1) and P-selectin (CD62P) binding site expression was not altered. Mild dose-dependent suppression of TEG-MA was seen with PEG-20k using platelet poor plasma. Erythrocyte Sedimentation Rates (ESR) were dramatically accelerated after dilution with 10% PEG-20k, which was competitively blocked by smaller PEG polymers, suggesting nonspecific PEG-20k cell binding effects.
PEG-20k creates a mild hypocoagulative state in whole blood at concentrations ≥10%, which may be due to platelet-PEG interactions at the IIb/IIIa interface with lesser effects on fibrin polymerization. This interaction may cause a functional thrombasthenia induced by nonspecific platelet surface passivation by the PEG polymer.
新型含聚乙二醇聚合物(PEG-20k)的晶体溶液可产生显著的复苏效果,但剂量依赖性地产生低凝状态。本研究的目的是探讨这种效应的可能机制。基于先前的血栓弹力图数据,我们假设这种效应主要是由于血小板与聚合物的相互作用。
从健康志愿者的枸橼酸盐全血中体外 10%稀释晶体液,并检测凝血和血小板功能。具体测试包括凝血酶原时间(PT)、活化部分凝血活酶时间(aPTT)、纤维蛋白原和血管性血友病因子(vWf)活性、凝血酶生成、有和无血小板图谱的血栓弹力图、血小板流式细胞术和红细胞沉降率。
纤维蛋白原和 vWF 活性、PT 和 aPTT 不受 PEG-20k 稀释的影响。PEG-20k 轻度抑制凝血酶活性(TTP-20%)。血小板图谱显示,PEG-20k 显著抑制 ADP 和花生四烯酸诱导的血小板聚集的%抑制率更高,但直接 ADP 激活的 gpIIa/IIIb(PAC1)和 P-选择素(CD62P)结合位点表达未改变。使用血小板缺乏血浆时,PEG-20k 轻度剂量依赖性抑制 TEG-MA。PEG-20k 稀释后红细胞沉降率(ESR)显著加快,这被较小的 PEG 聚合物竞争性阻断,提示存在非特异性 PEG-20k 细胞结合效应。
PEG-20k 在全血中的浓度≥10%时会产生轻度低凝状态,这可能是由于 IIb/IIIa 界面处的血小板-PEG 相互作用,对纤维蛋白聚合的影响较小。这种相互作用可能导致非特异性血小板表面钝化引起的功能性血小板无力症。